ILMN - Illumina, Inc.
| Previous Close | 298.55 |
| Open | 297.79 |
| Bid | 293.14 x 800 |
| Ask | 293.00 x 800 |
| Day's Range | 291.00 - 298.20 |
| 52 Week Range | 268.62 - 380.76 |
| Volume | 1,733,987 |
| Avg. Volume | 1,126,653 |
| Market Cap | 43.1B |
| Beta (3Y Monthly) | 1.35 |
| PE Ratio (TTM) | 51.26 |
| EPS (TTM) | 5.72 |
| Earnings Date | Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 331.43 |
- Yahoo Finance Video•8 days ago
Illumina nosedives as company cuts revenue outlook
Shares of the genetics company slid after cutting its second-quarter revenue expectations and slashed its full-year guidance. Yahoo Finance's Jared Blikre joins Seana Smith on 'The Ticker' to discuss.
- Motley Fool•13 hours ago
Here's Why Pacific Biosciences Is Tumbling Today
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
- TheStreet.com•2 days ago
Here's 2 Very Lucrative Trades From My New Trading Venture
The model I have developed for my new trading venture, Excelsior Capital Partners, has already produced two very lucrative trades. While my valuation methodology will remain proprietary to Excelsior, I am not giving anything away by noting that it is based on publicly available financial data and estimates. Well, some are, of course, and the bidding up of implied volatility in options contracts before earnings reports (this is especially apparent in Netflix's option chain) turned my trades in ILMN and NFLX from great to merely very good.
- Zacks•2 days ago
EXEL or ILMN: Which Is the Better Value Stock Right Now?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
- Business Wire•4 days ago
Illumina Expands Genomics Accelerator to Cambridge, UK
Partners with leading European venture capital firms to build breakthrough genomics startups
- Zacks•5 days ago
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
Illumina (ILMN) closed the most recent trading day at $302.29, moving -0.9% from the previous trading session.
- Motley Fool•8 days ago
What Happened in the Stock Market Today
On a record day for the major benchmarks, Illumina issued a warning, and Novartis and Amgen reported the failure of an Alzheimer's drug.
- InvestorPlace•8 days ago
Nasdaq Today: Amazon Prime Day; Facebook Settles With FTC
A trifecta of perfection: We had record highs in the S&P 500, Dow Jones and Nasdaq today. Shareholders in the PowerShares QQQ ETF (NASDAQ:QQQ) have little to complain about as tech stock continues to mash out higher highs over the past few sessions.Source: Shutterstock That's as FAANG stocks mostly lag and while rate cuts are likely.That said, it's not expected to be an amazing quarter when it comes to earnings. Companies are warning about their upcoming results, while analysts' estimates are looking at year-over-year declines for many names.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBlame it on tough comps from tax cuts, tariff wars or what have you. It's not a perfect operating environment and with stocks near all-time highs, investors are either willing to overlooking a few quarters of underperformance and pay a higher valuation for earnings or they area simply too optimistic. We'll know soon enough when we start seeing these companies report. Facebook SettlementFacebook (NASDAQ:FB) shares spiked into the close on Friday, ending the session higher by 1.8%. Reports surfaced moments before the close that the company had come to terms on a $5 billion settlement with the FTC. The deal is expected to have some other privacy restrictions as well. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond While $5 billion is a lot of cabbage, it's roughly the same amount that FB set aside to pay for such an event. Clearing this obstacle removes an unknown event for investors, who like clarity and having uncertainty removed. Movers in the Nasdaq TodayIllumina (NASDAQ:ILMN) shares sank more than 15% on the day after the company warned about its upcoming results. This caught investors way off guard, considering the company just beat and raised estimates a few months ago. It's not a good look for the genomics company, as it now hovers in no man's land. (Here's the trade setup for ILMN stock now).One could argue that it also weighed on Invitae (NASDAQ:NVTA), although the company's $50 million acquisition could be what's shaking up the stock price. Down 1.75% on the day, it's at least worth pointing out.Square (NYSE:SQ) stock jumped almost 4% on Friday, giving it a 10% gain over the past few days. The stock has seen some positive analyst commentary over the past few days, with the latest coming from Citigroup on Friday. While the stock is running into some resistance, many have it on breakout watch.JB Hunt (NASDAQ:JBHT) caught a big bid on Friday, rising over 6% on the day. However, currently trading hands for around $93 apiece, shares are well off the 52-week highs near $130. Be careful with this one, which reports earnings Monday.The $45 billion technology consulting company Infosys (NYSE:INFY) reported earnings on Friday. Shares hit new 52-week highs on the day, despite missing revenue estimates and reporting in-line earnings results. Better-than-expected guidance and an increase in its capital return plan likely helped, though.Memory and memory equipment stocks were also in focus in the Nasdaq today, as Lam Research (NASDAQ:LRCX), Western Digital (NASDAQ:WDC) and Micron (NASDAQ:MU) all put together a strong session. Micron is flirting with prior resistance, but a move over $44 to $45 could trigger a breakout. All About AmazonShares of Oracle (NASDAQ:ORCL) slipped 30 basis points on Friday after the company lost its court case against the Pentagon. The $10 billion cloud contract will now go to either Amazon (NASDAQ:AMZN) or Microsoft (NASDAQ:MSFT). But that's far from the only reason Amazon stock is in the news day.First, the company's much-discussed Prime Day is set to start next week. Prime Day will kick off on July 15th and run through the 16th. The made-up shopping event isn't unlike Alibaba's (NYSE:BABA) Single's Day, while Amazon now attracts others competitors into mix as well. Companies like Best Buy (NYSE:BBY), Target (NYSE:TGT) and Walmart (NYSE:WMT) will be running specials too, trying to keep customers away from the e-commerce juggernaut.As the smart-speaker battle heats up, Amazon is reportedly looking to better its game. The company wants to roll out a high-end Echo device, which could arrive next year. Further, Amazon is also working on an Alexa-powered robot. Codenamed Vesta, the devices apparently will not be ready for mass production this year. * 7 Stocks to Buy for Monster Growth in the Second Half of 2019 Last but certainly not least, Amazon's game-streaming Twitch platform logged more than 2.7 billion hours worth of streaming in the second quarter. For the industry, that accounted for more than 70% of the total. The next closest was Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) YouTube Live at 735 million hours and 19.5% market share. It was Twitch's second-biggest quarter ever.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AMZN and GOOGL. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post Nasdaq Today: Amazon Prime Day; Facebook Settles With FTC appeared first on InvestorPlace.
- Investor's Business Daily•8 days ago
This Genomics Stock Just Lost A Breakout — Why Analysts Still Like It
Illumina crashed Friday after the genomics company preannounced a $52 million shortfall in second-quarter sales. Illumina cited slower direct-to-consumer and government initiative sales.
- InvestorPlace•8 days ago
4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB
The stock market is slowly but surely pushing higher. It seems as though the bulls are reluctant to run too far, too fast. At the same time, the bears simply can't garner any staying power when it comes to pushing this market lower. At least not while rate cuts are on the way. Let's look at a few top stock trades for next week. Top Stock Trades for Monday 1: Johnson & Johnson Click to EnlargeShares of Johnson & Johnson (NYSE:JNJ) were smacked lower on Friday, falling over 4%. The stock is approaching the same level we flagged earlier in the year, near $130.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis level is currently acting as support, but has played a key role over the past 12 months. If JNJ stock falls down to this level, it may be worth investors nibbling at on the long side. Keep in mind, J&J reports earnings next week. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond If it hold this mark on an earnings decline, that's even better. Top Stock Trades for Monday 2: Square Click to EnlargeWe had Square (NYSE:SQ) on watch for a break higher, and that's exactly what we've gotten this week. The stock is up big over the past four trading sessions, rallying over 10%.For the short-term traders in this name, it would be prudent to book some of these gains with SQ stock heading straight into prior resistance.From here, let's see how SQ stock behaves. Does it pullback and consolidate a bit? Do shares push through resistance, which turns to support?I would love to see SQ stock coil under this level for a few days while holding up above $80. A breakout could Square flying higher, but the more rest it has before the breakout, the more powerful the move can be. On a decline, see that $78 holds as support. If it doesn't, $75 is on the table. Top Stock Trades for Monday 3: Illumina Click to EnlargeIt was a tough day to be a shareholder in Illumina (NASDAQ:ILMN). The stock plunged more than 15% after management warned about a big shortcoming in earnings.The action on Thursday spoke clearly. However, investors used the pullback to the 21-day moving average as an opportunity to get long rather than an opportunity to exit the name once steep channel support gave way.Given how big of a run ILMN has been on, you can't blame dip-buyers too much on this one. One day later and the stock is down huge. Its inability to stay above the 200-day moving average near $317 or the 61.8% retracement near $311 doesn't bode well for bulls. Under prior downtrend resistance (purple line) just adds salt to the wound.The longer shares stay below $311, the worse off bulls are. Let's give this one a few days to see where it settles down at. If it reclaims the $311 mark quickly, then we at least have a point of reference to use on the downside. Top Stock Trades for Monday 4: Aurora Cannabis Click to EnlargeYesterday we wrote about the bearish setup in Canopy Growth (NYSE:CGC) with its descending triangle formation. On Friday the stock plunged more than 7% and Aurora Cannabis (NYSE:ACB) isn't doing much better, down more than 5%.ACB is setting up the same descending triangle formation that CGC is and it's playing out exactly the same. Below the $7 to $7.25 area is very troubling for ACB. A rally back to this area and a failure to reclaim it sets it up for more downside. * 7 Stocks to Buy for Monster Growth in the Second Half of 2019 Be careful with this one. I wouldn't touch this one on the long side with a chart like this.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post 4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB appeared first on InvestorPlace.
- InvestorPlace•8 days ago
4 Healthcare Stocks That Are Feeling Sick
While the broad U.S. equity market is pushing confidently to new all-time highs, healthcare stocks are lagging badly. The entire sector has come under pressure after President Donald Trump's effort to lower drug prices high a legal roadblock when a judge blocked a new requirement to list prices in commercials. The Trump Administration also reversed its plan to curb drug rebates for government healthcare plans.The pressure isn't slowing down, with the Health Care Select SPDR (NYSEARCA:XLV) cutting down out of a multi-week consolidation range to put an end to a three-month uptrend. This also marks a turnaround at resistance from the early December highs and sets up a decline back to the mid-April lows. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond A number of big players in the sector are lagging badly. Here are four healthcare stocks to sell now:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare Stocks to Sell: Johnson & Johnson (JNJ)Shares of Johnson & Johnson (NYSE:JNJ) are dropping hard, down more than 4% on Friday as I write this and returning to lows not seen since early June. The move cuts below the stock's 200-day moving average and marks an inability to challenge the prior highs from back in December. The company continues to be dogged by legal risks related to baby powder asbestos claims.The company will next report results on July 16 before the bell. Analysts are looking for earnings of $2.42 per share on revenues of $20.4 billion. When the company last reported on April 16, earnings of $2.10 beat estimates by six cents on a 0.1% rise in revenues. Abbott Laboratories (ABT)Abbott Laboratories (NYSE:ABT) shares have fallen below their 20-day moving average for the first time since late May in what looks like the latest pullback within a secular uptrend that has been in play since 2016. Barclays analysts recently highlighted the company's impressive 7.1% organic revenue growth rate but noted very high investor expectations. Some profit taking should be expected. * 10 Stocks Driving the Market to All-Time Highs (And Why) The company will next report results on July 17 before the bell. Analysts are looking for earnings of 80 cents per share on revenues of $8 billion. When the company last reported on April 17, earnings of 63 cents per share beat estimates by a penny on a 2% rise in revenues. Intuitive Surgical (ISRG)Shares of Intuitive Surgical (NASDAQ:ISRG) are threatening to fall back below their 200-day moving average after struggling to reclaim that level after a nasty 22% decline from its mid-April high. This marks a continuation of a sideways range going back to the summer of 2018. The company is a maker of robotic surgical systems.The company will next report results on July 18 after the close. Analysts are looking for earnings of $2.87 per share on revenues of just over $1 billion. When the company last reported on April 18, earnings of $2.61 missed estimates by nine cents on a 14.9% rise in revenues. Illumnia (ILMN)Shares of Illumnia (NASDAQ:ILMN), which provides sequencing solutions for genetic analysis, is suffering a decline of more than 16% in mid-day trading after management guided second-quarter revenues below consensus estimates. Sales growth was impacted by lower than expected contributions from genomics initiatives. Shares were downgraded by analysts at Bank of America Merrill Lynch from buy to sell. Earlier this week, the stock hit an all-time high. * 7 Retail Stocks to Buy for the Second Half of 2019 ISRG stock will next report results on July 29 after the close. Analysts are looking for earnings of $1.42 per share on revenues of $885.6 million. When the company last reported on April 25, earnings of $2.56 beat estimates by 30 cents per share on an 8.2% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post 4 Healthcare Stocks That Are Feeling Sick  appeared first on InvestorPlace.
- Motley Fool•8 days ago
Here's Why NanoString Technologies Stock Soared 104.7% in the First Half of 2019
Investors are excited (perhaps a little too excited) about a new opportunity in immuno-oncology.
- Market Realist•8 days ago
Illumina Tanks on Reduced Revenue Forecast
The dramatic drop in Illumina’s stock mainly reflects investor concerns over downward revisions in revenue forecasts across all business areas.
- InvestorPlace•8 days ago
Illumina News: Why ILMN Stock Is Plummeting
Illumina news for Friday concerning early results for the second quarter of 2019 is hitting ILMN stock hard.Source: Shutterstock Illumina (NASDAQ:ILMN) says that it is expecting revenue for the second quarter of the year to come in at around $835 million. This would have revenue coming in above the $835 million reported in the same time of 2018. However, that's some majorly bad news for ILMN stock with Wall Street expecting revenue of $880.63 million for the quarter.The Illumina news release with the early estimates note that there are a few factors that kept its revenue from reaching full potential during the quarter. Starting off is a $30 million hit from population genomics initiatives. This originally would have had a large amount of sales closing in June, but has been pushed back to later this year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIllumina also notes that it expects revenue to be $10 million lower due to weakness in the direct-to-consumer market. It also pegs another $10 million in lower revenue on its underperforming non-high-throughput sequencing systems and consumables. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The Illumina news also has the company altering its guidance for the full year of 2019. It says that it is now expecting revenue for the year to be 6% above revenue reported for the full year of 2018. The company says that it will provide more details about the guidance update when it release its earnings report for the second quarter of the year.ILMN stock was down 15% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond As of this writing, William White did not hold a position in any of the aforementioned securities.The post Illumina News: Why ILMN Stock Is Plummeting appeared first on InvestorPlace.
- Motley Fool•8 days ago
Stock Market News: Facebook Faces New Crypto Criticism; Illumina's Revenue Falls Short
The Dow Jones Industrial Average pushed further into record territory Friday morning.
- Motley Fool•8 days ago
Why Illumina Stock Is Tanking Today
Weak preliminary Q2 results are weighing heavily on the genomic sequencing specialist.
- Benzinga•8 days ago
BofA Double Downgrades Illumina After Thursday's 'Big Miss'
Illumina said Thursday it expects second-quarter revenue to be roughly flat year-over-year at $835 million, which is short of the $890 million expected, de Bruin said in a Friday note. On top of a weak second-quarter pre-announcement, Illumina also lowered its full-year sales growth expectations from 13%-14% to 6%.
- Investor's Business Daily•8 days ago
Dow Jones Hits Record Highs To Lead Stock Market Rally; Illumina Plunges
The Dow Jones industrials and the S&P; 500 set more record highs early Friday. Illumina stock plunged after a revenue warning.
- TheStreet.com•8 days ago
Illumina, One of My Short Stock Candidates, Shows Mediocre Growth
ILMN shares were down about 15% in Friday trading after they pre-announced a revenue miss for its second quarter.
- MarketWatch•8 days ago
Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch
Shares of Illumina Inc. plummeted 16% in active morning trading Friday, after Bank of America Merrill Lynch swung to being bearish from bullish in the wake of the genetics company's revenue warning. Analyst Derik de Bruin cut his rating two notches to underperform from buy, and slashed his price target to $290 from $355. That downgrade follows the company's disclosing late Thursday that it now expects second-quarter revenue of $835 million, below the FactSet consensus of $888.3 million. "The miss was particularly surprising to us given positive commentary from management in recent months, and the number of issues that cropped up in the quarter," de Bruin wrote in a note to clients. While he's still upbeat on Illumina's positioning in the DNA sequencing/genomics market, he now sees "few near-term catalysts." The stock, on track to suffer the biggest one-day drop since October 2016, was still up 1.8% year to date, while the Dow Jones Industrial Average has gained 17%.
- Barrons.com•8 days ago
Illumina Stock Is Plummeting but Analysts Still Favor Genome Company
Illumina, the company that makes the machines that fuel the current boom in personal genome sequencing, disclosed preliminary revenue figures on Thursday evening that fell well short of its own estimates, sending shares down 14% in premarket trading on Friday.
- Barrons.com•8 days ago
Illumina Stock Plunges While the Dow Is Rising for a Third Day
Stocks are poised to open higher as central banks in the U.S. and Europe set the stage for looser monetary policy.
- Investor's Business Daily•8 days ago
Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails
Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.
- Benzinga•8 days ago
The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...
